Oxford Asset Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Oxford Asset Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,767	Closed	-$99K	–	2049
2019 Q1	$99K	Buy	+10,767	New	+$109K	﹤0.01%	1572
2018 Q4	–	Sell	-57,633	Closed	-$796K	–	2222
2018 Q3	$796K	Buy	57,633 +45,650	+381%	+$618K	0.02%	1114
2018 Q2	$131K	Buy	+11,983	New	+$117K	﹤0.01%	1627
2017 Q3	–	Sell	-14,937	Closed	-$128K	–	1780
2017 Q2	$128K	Buy	+14,937	New	+$107K	﹤0.01%	1401

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oxford Asset Management's KIN Position: Q2 2019 in Review

Oxford Asset Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2019, closing a stake of 10,767 shares — an estimated $99K sold.

Oxford Asset Management first reported a position in KIN in Q2 2017 and held it in 4 quarters. The position peaked at $796K in Q3 2018. 75 funds tracked by Wall St. Rank hold KIN as of Q2 2019.

Oxford Asset Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2019 after selling out during the quarter.
Oxford Asset Management sold 10,767 Kindred Biosciences, Inc. shares in Q2 2019, an estimated $99K.
Oxford Asset Management first reported a position in Kindred Biosciences, Inc. in Q2 2017 and held it in 4 quarters.
Oxford Asset Management's Kindred Biosciences, Inc. position peaked at $796K in Q3 2018.
75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2019.

Based on Oxford Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.